uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Oslo Univ Hosp, Dept Pathol, Sognsvannsveien 20, N-0372 Oslo, Norway..
Oslo Univ Hosp, Dept Specialised Endocrinol, Sognsvannsveien 20, N-0372 Oslo, Norway.;Univ Oslo, Fac Med, Klaus Torgardsvei 3, N-0372 Oslo, Norway..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
Copenhagen Univ Hosp, Rigshosp, Dept Pathol, Frederik Vs Vei 11, DK-2100 Copenhagen, Denmark..
Show others and affiliations
2016 (English)In: Pituitary, ISSN 1386-341X, E-ISSN 1573-7403, Vol. 19, no 4, 407-414 p.Article in journal (Refereed) PublishedText
Abstract [en]

Inactivating mutations of isocitrate dehydrogenase (IDH) 1 and 2, mitochondrial enzymes participating in the Krebs tricarboxylic acid cycle play a role in the tumorigenesis of gliomas and also less frequently in acute myeloid leukemia and other malignancies. Inhibitors of mutant IDH1 and IDH2 may potentially be effective in the treatment of the IDH mutation driven tumors. Mutations in the succinate dehydrogenase, the other enzyme complex participating in the Krebs cycle and electron transfer of oxidative phosphorylation occur in the paragangliomas, gastrointestinal stromal tumors, and occasionally in the pituitary adenomas. We aimed to determine whether the IDH1(R132H) mutation, the most frequent IDH mutation in human malignancies, occurs in pituitary adenomas. We performed immunohistochemical analysis by using a monoclonal anti-IDH1(R132H) antibody on the tissue microarrays containing specimens from the pituitary adenomas of different hormonal types from 246 patients. In positive samples, the status of the IDH1 gene was further examined by molecular genetic analyses. In all but one patient, there was no expression of mutated IDH1(R132H) protein in the tumor cells by immunohistochemistry. Only one patient with a recurring clinically non-functioning gonadotroph adenoma demonstrated IDH1(R132H)-immunostaining in both the primary tumor and the recurrence. However, no mutation in the IDH1 gene was detected using different molecular genetic analyses. IDH1(R132H) mutation occurs only exceptionally in pituitary adenomas and does not play a role in their pathogenesis. Patients with pituitary adenomas do not seem to be candidates for treatment with the inhibitors of mutant IDH1.

Place, publisher, year, edition, pages
2016. Vol. 19, no 4, 407-414 p.
Keyword [en]
Pituitary adenoma, Isocitrate dehydrogenase, IDH1(R132H), Immunohistochemistry, Tissue microarrays
National Category
Endocrinology and Diabetes
URN: urn:nbn:se:uu:diva-300440DOI: 10.1007/s11102-016-0720-7ISI: 000379350000009PubMedID: 27097804OAI: oai:DiVA.org:uu-300440DiVA: diva2:951529
Available from: 2016-08-09 Created: 2016-08-09 Last updated: 2016-08-09Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Casar-Borota, OliveraSundström, Magnus
By organisation
Department of Immunology, Genetics and Pathology
In the same journal
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 14 hits
ReferencesLink to record
Permanent link

Direct link